Pangolin coronavirus xCoV and application thereof and application of medicine in resisting coronavirus infection

• Main Authors: WANG LIQIN, SONG LIHUA, LIU WENLI, AN XIAOPING, LIU ZHENDONG, FAN HUAHAO, TONG YIGANG
• Format: Patent
• Language: Chinese; English
• Published: 29.06.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The invention provides a coronavirus separated from pangolin. The coronavirus is named as pangolin coronavirus xCoV, the homology of the coronavirus xCoV and S protein of SARS-COV-2 reaches 92.5%, receptors of xCoV infected cells and the SARS-COV-2 are consistent and are angiotensin converting enzyme 2 (ACE2). However, the xCoV does not infect people, is very safe to people, can be used for screening active drugs and vaccines for resisting the SARS-COV-2 virus, and can also be used for preparing attenuated vaccines or inactivated vaccines for resisting the SARS-COV-2 virus. Based on the pangolin coronavirus xCoV, a plurality of active compounds with anti-coronavirus activity are obtained by screening, EC50, CC50 and SI evaluation is performed on cepharanthine (stephanine), silamectin and mefloquine hydrochloride (mefloquine) in the active compounds, and the xCoV inhibition mechanism of cepharanthine is analyzed and researched through transcriptome sequencing. 本发明提供一种从穿山甲中分离的冠状病毒，命名为穿山甲冠状病毒xCoV，其与SARS-COV-2的S蛋